This article is more than 5 years old. Information may no longer be current.
Lanreotide for ADPKD shows few benefits over standard care
Click Here to Manage Email Alerts
SAN DIEGO — Lanreotide treatment for patients with later-stage autosomal dominant polycystic kidney disease (ADPKD) did not appear to slow patients’ decline in kidney function compared with standard care, according to data presented at ASN Kidney Week.
The goal of the study, led by Esther Meijer, PhD, of the University of Groningen, and colleagues, was to determine whether somatostatin analogue lanreotide did slow the rate of patients’ loss of kidney function in individuals with late stage ADPKD.
Investigators conducted the clinical trial at four outpatient clinics in the Netherlands. The study comprised 309 patients aged between 18 and 60 years with an estimated glomerular filtration rate (eGFR) of 30 to 60 mL/min/1.73 m2.
Researchers randomly assigned patients into two groups. One group received 120 mg of lanreotide administered subcutaneously every four weeks, in addition to standard care. The control group received only standard care. Follow-up analysis of the trial ended in August 2017 after 2.5 years.
The primary measurement for outcome was the annual change in eGFR over the 2.5-year treatment period. Secondary outcomes included the change in eGFR before and after treatments, worsening kidney function, change in kidney volume and quality of life.
In total, 261 participants completed the trial. Researches noted that the rate of eGFR decline showed no significant difference between standard care, at −3.53 vs. −3.46 mL/min/1.73 m2 per year. Investigators found results for eGFR before and after treatment, worsening kidney function and quality of life of the patients. However, total kidney growth rate in the lanreotide group was slowed by −1.33% per year.
More research is required to determine whether the results hold true for patients in a more racially diverse population considering the individuals with ADPKD in this study were predominantly white. – by Kristine Houck, MA, ELS, and Scott Buzby
Reference:
Meijer E, et al. JAMA. 2018; doi:10.1001/jama.2018.15870. Presented at: ASN Kidney Week; San Diego; Oct. 23-28, 2018.
Disclosure: This study was supported by grants from the Dutch Kidney Foundation and the Dutch Ministry of Economic Affairs and IPSEN Farmaceutica BV provided an unrestricted grant.